Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
|Poll|June 3, 2022
The Role of Psychedelics in Psychiatry: Helpful or Hoax?
Author(s)Psychiatric Times Editors
What are your thoughts on psychedelics?
Advertisement
Some say we are undergoing a
Do you think psychedelics can play a productive role in addressing psychiatric disorders?
Would you recommend psychedelics to your patients?
Have you referred your patients for psychedelic treatment/have any one of your patients received psychedelic-assisted therapy?
We want to know more about your thoughts and experiences with psychedelics and clinical practice! Write to us at
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
3
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
4
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
5